OphthalmologyWeb
Rho-kinase inhibitors are known to affect actomyosin cytoskeletal networks and have been shown to significantly increase outflow facility in several non-human
in vitro and
in vivo models. But a recent study may suggest why (
Exp Eye Res. 2008 Feb;86(2):271-81). Researchers Lu, Overby, et al, used a bovine system to explore the effects of rho-kinase inhibitor Y-27632 on hydrodynamic outflow patterns, inner wall morphology, and juxtacanalicular connective tissue. Their data suggest that the underlying mechanism of efficacy for this novel IOP-lowering agent is by opening up the junction between the inner wall and juxtacanalicular connective tissue, thereby increasing aqueous outflow.